1001079-80-6

Basic information

• Product Name: lutein disuccinate
• Synonyms: lutein disuccinate
• CAS NO: 1001079-80-6
• Molecular Weight: 769.031
• Mol File: 1001079-80-6.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: lutein disuccinate(CAS DataBase Reference)
• NIST Chemistry Reference: lutein disuccinate(1001079-80-6)
• EPA Substance Registry System: lutein disuccinate(1001079-80-6)

Safety Data

• Hazardous Substances Data: 1001079-80-6(Hazardous Substances Data)

Upstream product

• 108-30-5 succinic acid anhydride 
• 116947-92-3 lutein 
• 127-40-2 lutein 
• 7481-64-3 all-trans lutein 

Relevant articles and documents

Optimization of the ultrasound-assisted synthesis of lutein disuccinate using uniform design

The ultrasound-assisted synthesis of lutein disuccinate from all-trans lutein (AL) and succinic anhydride (SA) was investigated in this study. Triethylamine was used as the catalyst. Based on the single-factor experiments, a 7-level-3-factor uniform desig

WATER-DISPERSIBLE CAROTENOIDS, INCLUDING ANALOGS AND DERIVATIVES

A chemical composition; comprising one or more carotenoid analogs or derivatives having a structure (I), (II) and (III) where each R3 is independently hydrogen or methyl, and where each R1 and R2 are independently wherein each R5 is independently hydrogen, -OH, or -OR6, wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl-N+ (R7)3; -aryl-N+(R7)3; -alkyl-CO2R7; -aryl-CO2R7; -alkyl-CO2; -aryl-CO2; -CO2R8; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; -C(O)- (CH2)0-CO2R9; a nucleoside residue, or a co-antioxidant; wherein R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl or a co-antioxidant; wherein R9 is hydrogen; alkyl; aryl; -P(0)(OR8)2; -S(0)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and wherein n is 1 to 9. The compounds are useful for the inhibition and amelioration of diseases resulting in change and/or loss of vision.

Carotenoid ether analogs or derivatives for controlling C-reactive protein levels

A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one j e substituent. The substituent may be coupled to the cyclic ring with an ether functionality.